9 reasons NOT to do a tech transfer

For global Regulatory Affairs Directors.

A technology transfer can be the best decision for your manufacture – or, done wrong, it could be the worst. Our experts have identified 9 red flags to look out for before initiating a tech transfer.

Pharma manufacturing Arex Advisor

1. No back-up manufacturing site

Preferably, do not initiate a tech transfer unless a back-up manufacturing site is guaranteed, in case the transfer is unsuccessful. This can lead to serious out of stock-situations.

2. History of deviations at accepting site

If the proposed site has a history of major deviations, FDA Warning Letters, etc. – this is a warning sign that there might be issues, also with future manufacturing.

3. High costs to meet requirements

If, for instance, costly bioequivalence studies are required for regulatory approval, the cost of the transfer might become higher than predicted, or even manageable.

4. Instability at leaving site

Stable formulation, manufacture and control at the leaving site is crucial for the transfer to be successful. If this is not secured, do not initiate a transfer.

5. Lack of support from leaving site

The leaving site must provide a robust support to accepting site in the transfer process. Compromised support means a high risk of the transfer being unsuccessful.

6. Missing quality agreements

Unless comprehensive quality agreements are in place, do not initiate a tech transfer. If (when) running into problems, clearly defined responsibilities are paramount.

7. Product not being marketed

Confirm with your marketing functions that the product to be transferred actually is going to be marketed!

8. Insufficient analytical method

Analytical method transfer needs to be secured before initiating any manufacturing activities. If the accepting site is unable to analyse the product, no transfer can be pursued.

9. Failed trial batches

Failed trial batches is an obvious sign that the accepting site is not capable of producing the desired product.

Are you looking for tech transfer support?

Arex has the experience and expertise to help you navigate tech transfer challenges.

Read more about our services here:

Analytical method and validation advice

Technology transfer support

CMC services

Pharma manufaturing Tech Transfer advice Arex Advisor

Staffan Thunell

Founding partner

BSc Economics and BA

Staffan has a long background in entrepreneurship within the life science industry. He has 20+ years experience from posit­ions as Founder, Chair­man, CEO and CFO within medical affairs consulting and small pharma. Previously Staffan worked in executive positions in big pharma and specialty pharma companies.